2017


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2017/№S1

Современные представления о сложной связи между фибрилляцией предсердий и ишемической болезнью сердца и об оптимальной тактике антикоагулянтной терапии для профилактики эмболий в сосуды большого круга кровообращения

Гиляревский С. Р.1, 2, Голшмид М. В.1, Кузьмина И. М.2, Синицина И. И.1
1 – ГБОУ ДПО «РМАПО» МЗ РФ, 123995, Москва, ул. Баррикадная, д. 2/1
2 – НИИ «Скорой помощи» им. Н. В. Склифосовского, 129090, Москва, Б. Сухаревская пл., д. 3

Ключевые слова: фибрилляция предсердий, ишемическая болезнь сердца, антикоагулянты, ривароксабан

DOI: 10.18087/cardio.2399

В статье обсуждается проблема поиска оптимальной тактики пероральных антикоагулянтов для профилактики развития тромбозов и эмболий, обусловленных заболеванием сердца, как у больных с фибрилляцией предсердий, так и синусовым ритмом. Рассматриваются сложная двунаправленная связь между фибрилляцией предсердий и развитием атеросклероза коронарных артерий, а также возможные механизмы развития ИМ у больных с фибрилляцией предсердий. Приводятся доказательные данные, которые могут использоваться при решении вопроса о выборе антикоагулянта с целью профилактики развития тромбозов и эмболий, обусловленных заболеванием сердца с учетом как эффективности, так и безопасности, установленной в ходе выполнения рандомизированных клинических исследований.
  1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.
  2. Vardas P, Andrikopoulos G, Baroutsou B, ODYSSEY Investigators. A Greek Prospective Observational Study of Cardiovascular Morbidity and Mortality in Patients with Atrial Fibrillation. Hellenic J Cardiol. 2015;56(6):475–94.
  3. Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández A-I, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2016;68(23):2508–21. DOI:10.1016/j.jacc.2016.09.944.
  4. Nieuwlaat R, Capucci A. Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation. European Heart Journal. 2005;26(22):2422–34. DOI:10.1093/eurheartj/ehi505.
  5. Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE. 2011;6(9):e24964. DOI:10.1371/journal.pone.0024964.
  6. Cameron A, Schwartz MJ, Kronmal RA, Kosinski AS. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol. 1988;61(10):714–7.
  7. Zielonka A, Tkaczyszyn M, Mende M, Nowak W, Rekucki K, Soczomski P et al. Atrial fibrillation in outpatients with stable coronary artery disease: results from the multicenter RECENT study. Pol Arch Med Wewn. 2015;125(3):162–71.
  8. Motloch LJ, Reda S, Larbig R, Wolff A, Motloch KA, Wernly B et al. Characteristics of coronary artery disease among patients with atrial fibrillation compared to patients with sinus rhythm. Hellenic J Cardiol. 2017; DOI:10.1016/j.hjc.2017.03.001.
  9. Chaikriangkrai K, Valderrabano M, Bala SK, Alchalabi S, Graviss EA, Nabi F et al. Prevalence and Implications of Subclinical Coronary Artery Disease in Patients With Atrial Fibrillation. Am J Cardiol. 2015;116(8):1219–23. DOI:10.1016/j.amjcard.2015.07.041.
  10. Klass M, Haywood LJ. Atrial fibrillation associated with acute myocardial infarction: a study of 34 cases. Am Heart J. 1970;79(6):752–60.
  11. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30(9):1038–45. DOI:10.1093/eurheartj/ehn579.
  12. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107–14. DOI:10.1001/jamainternmed.2013.11912.
  13. Soliman EZ, Lopez F, O’Neal WT, Chen LY, Bengtson L, Zhang Z-M et al. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015;131(21):1843–50. DOI:10.1161/CIRCULATIONAHA.114.014145.
  14. Prizel KR, Hutchins GM, Bulkley BH. Coronary artery embolism and myocardial infarction. Ann Intern Med. 1978;88(2):155–61.
  15. Lau DH, Huynh LT, Chew DP, Astley CM, Soman A, Sanders P. Prognostic impact of types of atrial fibrillation in acute coronary syndromes. Am J Cardiol. 2009;104(10):1317–23. DOI:10.1016/j.amjcard.2009.06.055.
  16. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J. 1999;20(10):748–54.
  17. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS, OPTIMAAL investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J.2005;26(4):350–6. DOI:10.1093/eurheartj/ehi064.
  18. Mehta RH, Dabbous OH, Granger CB, Kuznetsova P, Kline-Rogers EM, Anderson FA et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol. 2003;92(9):1031–6.
  19. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008;94(7):867–73. DOI:10.1136/hrt.2007.134486.
  20. Wi J, Shin D-H, Kim J-S, Kim B-K, Ko Y-G, Choi D et al. Transient New-Onset Atrial Fibrillation Is Associated With Poor Clinical Outcomes in Patients With Acute Myocardial Infarction. Circ J. 2016;80(7):1615–23. DOI:10.1253/circj.CJ-15-1250.
  21. Yaghi S, Pilot M, Song C, Blum CA, Yakhkind A, Silver B et al. Ischemic Stroke Risk After Acute Coronary Syndrome. J Am Heart Assoc. 2016;5(7):e002590. DOI:10.1161/JAHA.115.002590.
  22. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19. DOI:10.1056/NEJMoa1112277.
  23. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006–10. DOI:10.1161/01.CIR.0000103131.70301.4F.
  24. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767–72.
  25. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43. DOI:10.1056/NEJM200003233421202.
  26. Rienstra M, Sun JX, Magnani JW, Sinner MF, Lubitz SA, Sullivan LM et al. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109(4):533–7. DOI:10.1016/j.amjcard.2011.09.049.
  27. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50(21):2021–8. DOI:10.1016/j.jacc.2007.06.054.
  28. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263–70. DOI:10.1016/j.jacc.2012.04.063.
  29. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol. 2013;61(8):852–60. DOI:10.1016/j.jacc.2012.11.046.
  30. Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol. 2000;75(2–3):227–32.
  31. Willoughby SR, Roberts-Thomson RL, Lim HS, Schultz C, Prabhu A, De Sciscio P et al. Atrial platelet reactivity in patients with atrial fibrillation. Heart Rhythm. 2010;7(9):1178–83. DOI:10.1016/ j.hrthm.2010.01.042.
  32. Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373(9658):155–66. DOI:10.1016/S0140-6736(09)60040-4.
  33. Xu B, Williams P, Burns AT. Acute myocardial infarction due to coronary artery embolus associated with atrial fibrillation. Acute Card Care. 2013;15(4):92–4. DOI:10.3109/17482941.2013.835828.
  34. Du X-Y, Hui P, Zheng Y. Coronary embolism causing acute inferior wall and ventricular myocardial infarction in a patient with rheumatic valvular heart disease: treatment with thrombus aspiration. Heart Surg Forum. 2015;18(3):E084-087.
  35. Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. J Am Heart Assoc. 2016;5(5). DOI:10.1161/JAHA.116.003347.
  36. Pastori D, Farcomeni A, Poli D, Antonucci E, Angelico F, Del Ben M et al. Cardiovascular risk stratification in patients with nonvalvular atrial fibrillation: the 2MACE score. Intern Emerg Med. 2016;11(2):199–204. DOI:10.1007/s11739-015-1326-1.
  37. Lee CJ-Y, Pallisgaard JL, Olesen JB, Carlson N, Lamberts M, Gislason GH et al. Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017;69(24):2901–9. DOI:10.1016/j.jacc.2017.04.033.
  38. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2009;361(12):1139–51. DOI:10.1056/NEJMoa0905561.
  39. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402. DOI:10.1001/archinternmed.2011.1666.
  40. Mahaffey KW, Stevens SR, White HD, Nessel CC, Goodman SG, Piccini JP et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014;35(4):233–41. DOI:10.1093/eurheartj/eht428.
  41. Tornyos A, Kehl D, D’Ascenzo F, Komócsi A. Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. Prog Cardiovasc Dis. 2016;58(5):483–94. DOI:10.1016/j.pcad.2015.12.001.
  42. Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992;32(3):196–209.
  43. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997;126(2):133–6.
  44. Crowther MA, Ginsberg JB, Kearon C, Harrison L, Johnson J, Massicotte MP et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999;159(1):46–8.
  45. Azoulay L, Dell’Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J. 2014;35(28):1881–7. DOI:10.1093/eurheartj/eht499.
  46. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG et al. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017;2(5):478–87. DOI:10.1001/jamacardio.2017.0063.
  47. Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis. 2007;18(3):193–9. DOI:10.1097/MCA.0b013e328012a964.
  48. Wang TY, Robinson LA, Ou F-S, Roe MT, Ohman EM, Gibler WB et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J. 2008;155(2):361–8. DOI:10.1016/j.ahj.2007.09.003.
  49. Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44(8):1557–66. DOI:10.1016/j.jacc.2004.05.084.
  50. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501–55. DOI:10.1093/eurheartj/ehq277.
  51. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334(17):1084–9. DOI:10.1056/NEJM199604253341702.
  52. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–12. DOI:10.1016/S0140-6736(06)68845-4.
  53. Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714–21. DOI:10.1093/eurheartj/ehp275.
  54. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126(10):1185–93. DOI:10.1161/CIRCULATIONAHA.112.114967.
  55. Ruiz-Nodar JM, Marín F, Sánchez-Payá J, Hurtado JA, Valencia-Martín J, Manzano-Fernández S et al. Efficacy and safety of drugeluting stent use in patients with atrial fibrillation. Eur Heart J. 2009;30(8):932–9. DOI:10.1093/eurheartj/ehp045.
  56. Sarafoff N, Ndrepepa G, Mehilli J, Dörrler K, Schulz S, Iijima R et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med. 2008;264(5):472–80. DOI:10.1111/j.1365-2796.2008.01989.x.
  57. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI:10.1093/eurheartj/ehw210.
  58. Lopes RD, Li L, Granger CB, Wang TY, Foody JM, Funk M et al. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. Am J Med. 2012;125(9):897–905. DOI:10.1016/j.amjmed.2012.04.006.
  59. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–15. DOI:10.1016/S0140-6736(12)62177-1.
  60. Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65(16):1619–29. DOI:10.1016/j.jacc.2015.02.050.
  61. Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;121(18):2067–70. DOI:10.1161/CIRCULATIONAHA.109.924944.
  62. Sherwood MW, Cyr DD, Jones WS, Becker RC, Berkowitz SD, Washam JB et al. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. JACC Cardiovasc Interv. 2016;9(16):1694–702. DOI:10.1016/j.jcin.2016.05.039.
  63. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423–34. DOI:10.1056/NEJMoa1611594.
  64. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI:10.1056/NEJMoa1009638.
  65. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.
  66. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708. DOI:10.1056/NEJMoa1105819.
  67. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781–9. DOI:10.1093/eurheartj/ehr113.
Гиляревский С. Р., Голшмид М. В., Кузьмина И. М., Синицина И. И. Современные представления о сложной связи между фибрилляцией предсердий и ишемической болезнью сердца и об оптимальной тактике антикоагулянтной терапии для профилактики эмболий в сосуды большого круга кровообращения. Кардиология. 2017;57(S1):312–322

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En